Abstract
The generating capacity of interleukin 1 (IL-1) and interleukin 2 (IL-2) by peripheral blood mononuclear cells (PBMNC) was measured in 40 patients with digestive cancer (20 localized and 20 disseminated) and 20 age- and sex-matched control subjects. The localized carcinoma patients showed normal IL-1 production and a significantly depressed IL-2 production (p<0.05) when compared to the healthy individuals. The disseminated carcinoma patients exhibited a significant impairment of both IL-1 and IL-2 production in comparison with the healthy controls (IL-1: p<0.001, IL-2: p<0.001) and the localized carcinoma patients (IL-1: p<0.001, IL-2: p<0.001). A significant correlation was observed between IL-1 and IL-2 generation in all the cancer patients (r=0.458, p<0.01). These results suggest that progressive tumor growth may result in decreased interleukin production by the host PBMNC, and that related mechanisms, which are more susceptable to lymphocytes than monocytes, may be involved in the impairment of both IL-1 and IL-2 production.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Catalona WJ, Chretien PB, Trachan EE. Abnormalities of cell-mediated immunocompetence in genitourinary cancer. J Urol 1974; 111: 229–232.
Chretien PB, Crowder WL, Gertner HR, Sample WF, Catalona WJ. Correlation of preoperative lymphocyte reactivity with clinical course of cancer patients. Surg Gynecol Obstet 1973; 136: 380–384.
Brugarolas A, Takita H. Immunological status in lung cancer. Chest 1973; 64: 427–430.
Gardner RJ, Frederick W, Preston FW. Prolonged skin homograft survival in advanced cancer and cirrhosis of the liver. Surg Gynecol Obstet 1962; 115: 399–402.
Garrioch DB, Good RA, Gatti RA. Lymphocyte response to PHA in patients with non-lymphoid tumors. Lancet 1970; 1: 618.
Zembala M, Mytar B, Popiela T, Asherson GL. Depressedin vitro peripheral blood lymphocyte response to mitogens in cancer patients: The role of suppressor cells. Int J Cancer 1977; 19: 605–613.
Low TLK, Goldstein AL. Thymosis: Isolation, structural studies, and biologic activities. In: Thymic hormones and lymphokines. New York: Plenum Press 1984; 21–35.
Farrar JJ, Benjamin WR, Hilfiker ML, Howard M, Farrar WL, Fuller-Farrar J. The biochemistry, biology and role of interleukin 2 in the induction of cytotoxic T cell and antibody forming B cell responses. Immunol Rev 1982; 63: 129–166.
Ravikumar T, Rodrick M, Steele G, Marrazo J, O’Dwyer P, Dodson T, King V. Interleukin generation in experimental colon cancer of rats: Effect of tumor growth and tumor therapy. JNCI 1985; 74: 893–898.
Mizel SB, Oppenheim JJ, Rosenstreich DL. Characterization of lymphocyte activating factor (LAF) produced by the macrophage cell lines, P338D. J Immunol 1978; 120: 1497–1503.
Mizel SB. Studies on the purification and structure-function relationships of murine lymphocyte activating factor (Interleukin 1). Mol Immunol 1980; 17: 893–895.
Suzuki R, Handa K, Itoh K, Kumagai K. Natural killer (NK) cells as a responder to interleukin 2 (IL-2): 1. Proliferative response and establishment of cloned cells. J Immunol 1983; 130: 981–987.
Maca R, Pange WR. Indomethacine sensitive suppressor cell activity in head and neck cancer patients pre and post radiation therapy. Cancer 1982; 50: 483–494.
Santos LB, Yamada FT, Scheinberg MA. Monocyte and lymphocyte interaction in patients with advanced cancer. Cancer 1985; 56: 1553–1558.
Pollac S, Micali A, Kinne DW, Enker WE, Geller N, Oettgen HF, Hoffmann MK. Endotoxin-inducedin vitro release of Interleukin-1 by cancer patients’ monocytes: Relation to stage of disease. Int J Cancer 1983; 32: 733–736.
Nakayama E, Asano S, Takuwa N, Yokota J, Miwa S. Decreased TCGF activity in the culture medium of PHA stimulated peripheral mononuclear cells from patients with metastatic cancer. Clin Exp Immunol 1983; 51: 511–516.
Monson JRT, Ramsden C, Guillou PJ. Decreased interleukin-2 production in patients with gastrointestinal cancer. Br J Surg 1986; 73: 483–486.
Ravikumar T, Glenn S Jr, Rodrick M, Ross D, Wilson R, Lahey S, Wright D, Munroe A, King V. Effects of tumor growth on interleukins and circulating immune complexes. Cancer 1984; 53: 1373–1378.
Hersey P, Bindon C, Czerniecki M, Spurling A, Wass J, McCarthy WH. Inhibition of interleukin-2 production by factors released from tumor cells. J Immunol 1983; 131: 2837–2842.
Rosenberg SA, Lotze MJ, Muul LJ, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skkiber JM, Shiloni E, Vetto JT, Seipp CA, Simpson C, Reichert CM. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985; 313: 1485–1492.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Haga, Y., Sakamoto, K., Yokoyama, Y. et al. Decreased interleukin generation in patients with cancer of the digestive system. A correlation between interleukin 1 and interleukin 2 production. The Japanese Journal of Surgery 18, 527–532 (1988). https://doi.org/10.1007/BF02471486
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02471486